Chronic inflammatory demyelinating polyradiculoneuropathy is a rare autoimmune-related condition that affects nerve signaling ...

The “go” decision was reached early, ahead of the company’s second quarter expected timeline. ・The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Dianthus Therapeutics Inc. DNTH shares are up during Monday’s premarket session following an early GO decision announced by the company based on an interim responder analysis in the Phase 3 CAPTIVATE ...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of ...

Shares of Dianthus Therapeutics rose after the company reached an early decision to move ahead with its phase 3 trial for Chronic Inflammatory Demyelinating Polyneuropathy, an autoimmune disorder. The ...

WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...

(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic ...

SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.